What lies ahead for Melbourne’s biotechnology, medical technology and pharmaceutical industry in 2019? Our annual “Hot or Not” discussion will explore the global trends for the coming year with 4 speakers each presenting a short “snap shot” of what is HOT and what is NOT going into 2019 in their area of interest and expertise.
Topics for discussion include:
• AI & IP – Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick
• Exosomes – Dr Ian Dixon, CEO & Founder, Exopharm Ltd (ASX-EX1)
• Consumer Health – Poppy Griffiths, Manager, Strategic Projects, Swisse Wellness
• JP Morgan conference insight – market/sector trends – Sam Cobb, Managing Director & Chief Executive Officer, Adalta
Read more about these presenters below.
Date: Thursday 7th February, 2019
Time: 4:00pm – 5:30pm followed by a networking session
Venue: Philips Ormonde Fitzpatrick, Level 16, 333 Collins Street Melbourne
Tickets: This event is now fully subscribed
Raffaele Calabrese, Patent Attorney, Phillips Ormonde Fitzpatrick
Raffaele has a background in electrical and electronic engineering, and a master’s degree in engineering specialising in information technology and telecommunications. He has had over ten years of professional experience in protecting inventions relating to ICT, software and engineering.
Raffaele began his intellectual property (IP) career in 2005 as a Technical Assistant with an IP firm in Adelaide. In 2007, he moved to Melbourne and joined a large IP firm, where he specialised in drafting and prosecuting patent applications in Australia and overseas. During this time, he also gained experience in assisting Australian and international clients with obtaining trade mark and design protection.
Raffaele’s background provides him with an in depth understanding of a wide range of electronic and mechanical inventions. He also has experience in protecting computer implemented inventions, including Fin Tech inventions, mining, energy and medical technologies.
Dr Ian Dixon, CEO & Founder, Exopharm Ltd
Dr Dixon brings to the Exopharm Board an extensive technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development.
In 2011, Dr Dixon Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP).
Dr Dixon is also a non-executive director of Noxopharm Ltd (ASX-NOX); a founder of Nyrada Inc.; a co-inventor of Nyrada drug NYX-330; founder of Genscreen Pty Ltd (2003-2018) and; former director of Cell Therapies Pty Ltd. Dr Dixon currently also serves as a part-time executive director of Medigard Ltd (ASX:MGZ).
Dr Dixon is a co-inventor of the LEAP Technology now owned by Exopharm.
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.
Sam Cobb, Managing Director & Chief Executive Officer, Adalta
Sam is the founding CEO of AdAlta and has over fifteen years’ experience in business development and commercialisation of early stage scientific technologies.
Prior to AdAlta, Sam was the Business Development Director at the Co-operative Research Centre for Diagnostics. Sam has also worked for the biotech start up companies Sensologix Inc and Nephrogenix Pty Ltd and at the University of Queensland’s technology commercialisation companies, Uniquest Pty Ltd and IMBcom Pty Ltd.
Sam has a Bachelor of Science, a Masters of Intellectual Property Law and has completed the Australian Institute of Company Directors course.
Poppy Griffiths, Manager, Strategic Projects, Swisse Wellness
Poppy Griffiths is a Strategic Marketing Specialist with over 12 years experience in marketing and communications, brand management, stakeholder engagement, and business development. Currently the Marketing & Communications Manager of Strategic Projects at global business Swisse Wellness, Poppy is passionately leading innovative Wellness focused investments that seek to drive improved health outcomes for Australians.
Her experience spans the corporate and not for profit sectors in the health, aviation and communications industries. Her roles have been located in both Australia and South East Asia, working with global teams in Europe, China and the US to launch new H&H Group (parent company of Swisse) Brand portfolio’s into Australia & New Zealand.
Poppy has Bachelor qualifications in Psychology from Melbourne University and a Masters of Business Management from Monash Business School.
As a passionate advocate for health promotion, Poppy is a media spokesperson and ambassador for the R U OK? Day organisation, a past Board member of national nutrition organisation, Nutrition Australia & Director of The One by One Foundation, supporting projects that improve the lives of children in Africa.